Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
NCT02138929Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2014
- Primary completion
- Jun 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib in esophageal adenocarcinoma (EAC), gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of LDE225 in Combination with Everolimus at 10 weeks. Started Nov 2014; status: completed.
02
Drugs
sonidegib
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02138929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138929.